Home Use of an Artificial Beta Cell in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The feasibility, safety, and efficacy of prolonged use of an artificial beta cell (closed-loop insulin-delivery system) in the home setting have not been established. METHODS: In two multicenter, crossover, randomized, controlled studies conducted under free-living home conditions, we compared closed-loop insulin delivery with sensor-augmented pump therapy in 58 patients with type 1 diabetes. The closed-loop system was used day and night by 33 adults and overnight by 25 children and adolescents. Participants used the closed-loop system for a 12-week period and sensor-augmented pump therapy (control) for a similar period. The primary end point was the proportion of time that the glucose level was between 70 mg and 180 mg per deciliter for adults and between 70 mg and 145 mg per deciliter for children and adolescents. RESULTS: Among adults, the proportion of time that the glucose level was in the target range was 11.0 percentage points (95% confidence interval [CI], 8.1 to 13.8) greater with the use of the closed-loop system day and night than with control therapy (P<0.001). The mean glucose level was lower during the closed-loop phase than during the control phase (difference, -11 mg per deciliter; 95% CI, -17 to -6; P<0.001), as were the area under the curve for the period when the glucose level was less than 63 mg per deciliter (39% lower; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0.5 to -0.1; P=0.002). Among children and adolescents, the proportion of time with the nighttime glucose level in the target range was higher during the closed-loop phase than during the control phase (by 24.7 percentage points; 95% CI, 20.6 to 28.7; P<0.001), and the mean nighttime glucose level was lower (difference, -29 mg per deciliter; 95% CI, -39 to -20; P<0.001). The area under the curve for the period in which the day-and-night glucose levels were less than 63 mg per deciliter was lower by 42% (95% CI, 4 to 65; P=0.03). Three severe hypoglycemic episodes occurred during the closed-loop phase when the closed-loop system was not in use. CONCLUSIONS: Among patients with type 1 diabetes, 12-week use of a closed-loop system, as compared with sensor-augmented pump therapy, improved glucose control, reduced hypoglycemia, and, in adults, resulted in a lower glycated hemoglobin level. (Funded by the JDRF and others; AP@home04 and APCam08 ClinicalTrials.gov numbers, NCT01961622 and NCT01778348.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Medtronic 780G, 113,114 CamAPS FX, 115,116 and Diabeloop 117 received CE mark for use in European countries;”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [115]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
The barrier of hypoglycemia in diabetes
Cryer, P. E. (2008) · Diabetes · doi:10.2337/db08-1084 · Cited by 725
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 3×
“Hyperglycemia related to infusion-set occlusion 0 6 (18) 4 (12) 0 0 2 (8) 0 0”
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602 · cited 2×
“Hyperglycemia related to infusion-set occlusion 0 6 (18) 4 (12) 0 0 2 (8) 0 0”
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Phillip, M., Battelino, T., Atlas, E., Kordonouri, O., Bratina, N., Miller, S., Biester, T., Avbelj Stefanija, M., Muller, I., Nimri, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206881 · Cited by 435
Wood, J. R., Miller, K. M., Maahs, D. M., Beck, R. W., DiMeglio, L. A., Libman, I. M., Quinn, M., Tamborlane, W. V., Woerner, S. E., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1959 · Cited by 415
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
McKnight, J. A., Wild, S. H., Lamb, M. J. E., Cooper, M. N., Jones, T. W., Davis, E. A., Hofer, S., Fritsch, M., Schober, E., Svensson, J., et al. (2015) · Diabetic Medicine · doi:10.1111/dme.12676 · Cited by 343 · cited 6×
“Knee-joint arthralgia 0 1 (3) 0 0 0 0 0 0”
InfluentialClosed-loop insulin delivery from bench to clinical practice
Hovorka, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.32 · Cited by 342 · cited 1×
“Gastroenteritis 0 2 (6) 3 (9) 0 0 0 0 0”
Self-citation
Cited by
Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities
Rodbard, D. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0417 · Cited by 737
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
“, 3–24 weeks) in the home setting.(14,18,38) Comparing our results to previous short-term studies is difficult.”
ResultChiang, J. L., Maahs, D. M., Garvey, K. C., Hood, K. K., Laffel, L. M., Weinzimer, S. A., Wolfsdorf, J. I., & Schatz, D. (2018) · Diabetes Care · doi:10.2337/dci18-0023 · Cited by 509
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton, M. D., Kanapka, L. G., Beck, R. W., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M., Ruedy, K. J., Jost, E., Carria, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004736 · Cited by 455
Self-citationKarges, B., Schwandt, A., Heidtmann, B., Kordonouri, O., Binder, E., Schierloh, U., Boettcher, C., Kapellen, T., Rosenbauer, J., & Holl, R. W. (2017) · JAMA · doi:10.1001/jama.2017.13994 · Cited by 452
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citationTauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Self-citation14. Children and Adolescents: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s014 · Cited by 367
New closed-loop insulin systems
Boughton, C. K., & Hovorka, R. (2021) · Diabetologia · doi:10.1007/s00125-021-05391-w · Cited by 270
Self-citationClosed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes
Stewart, Z. A., Wilinska, M. E., Hartnell, S., Temple, R. C., Rayman, G., Stanley, K. P., Simmons, D., Law, G. R., Scott, E. M., Hovorka, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602494 · Cited by 279
Self-citation13. Children and Adolescents: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s013 · Cited by 267
El-Khatib, F. H., Balliro, C., Hillard, M. A., Magyar, K. L., Ekhlaspour, L., Sinha, M., Mondesir, D., Esmaeili, A., Hartigan, C., Thompson, M. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32567-3 · Cited by 254
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
Closed-loop insulin delivery for glycemic control in noncritical care
Bally, L., Thabit, H., Hartnell, S., Andereggen, E., Ruan, Y., Wilinska, M. E., Evans, M. L., Wertli, M. M., Coll, A. P., Stettler, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805233 · Cited by 232
Self-citation13. Children and Adolescents: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s013 · Cited by 223
Coming of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223
“A concerted effort is underway to combine these advancements and develop the ‘artificial pancreas’, also known as the closed-loop system, to emulate the feedback, glucose-responsive functionality of the beta cell [8, 9].”
BackgroundMethodInfluentialSelf-citation14. Children and Adolescents: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s014 · Cited by 200
Benhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Transforming Diabetes Care Through Artificial Intelligence: The Future Is Here
Dankwa-Mullan, I., Rivo, M., Sepulveda, M., Park, Y., Snowdon, J., & Rhee, K. (2019) · Population Health Management · doi:10.1089/pop.2018.0129 · Cited by 217
13. Children and Adolescents: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s013 · Cited by 200
12. Children and Adolescents: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s012 · Cited by 194
ISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies
Sherr, J. L., Tauschmann, M., Battelino, T., de Bock, M., Forlenza, G., Roman, R., Hood, K. K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12731 · Cited by 197
“The longest outpatient RCT published to date by Thabit et al compared a model-predictive-control automated insulin delivery device to SAP for 12 weeks.(237) There were two sub studies included; (1) a cohort of 33 adult participants who used the system 24 hours per day, and (2) a child and adolescent study (n = 25) who…”
MethodSelf-citationChase, J. G., Preiser, J.-C., Dickson, J. L., Pironet, A., Chiew, Y. S., Pretty, C. G., Shaw, G. M., Benyo, B., Moeller, K., Safaei, S., et al. (2018) · BioMedical Engineering OnLine · doi:10.1186/s12938-018-0455-y · Cited by 189
“Thus, such an approach also opens the next technological door towards electronic and automated sensing, and eventually, closed loop care systems, as recently emerging with the artificial pancreas in type 1 diabetes [237–249].”
Background14. Children and Adolescents: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s014 · Cited by 165
Safety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 Diabetes
Forlenza, G. P., Pinhas-Hamiel, O., Liljenquist, D. R., Shulman, D. I., Bailey, T. S., Bode, B. W., Wood, M. A., Buckingham, B. A., Kaiserman, K. B., Shin, J., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0264 · Cited by 182
Trevitt, S., Simpson, S., & Wood, A. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815617968 · Cited by 173
“Recent published research.(31-37) Planned research: NCT02523131.”
Breton, M. D., Cherñavvsky, D. R., Forlenza, G. P., DeBoer, M. D., Robic, J., Wadwa, R. P., Messer, L. H., Kovatchev, B. P., & Maahs, D. M. (2017) · Diabetes Care · doi:10.2337/dc17-0883 · Cited by 179
14. Children and Adolescents: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s014 · Cited by 173
Stewart, Z. A., Wilinska, M. E., Hartnell, S., O’Neil, L. K., Rayman, G., Scott, E. M., Barnard, K., Farrington, C., Hovorka, R., & Murphy, H. R. (2018) · Diabetes Care · doi:10.2337/dc17-2534 · Cited by 168
“5% in 70–180mg/dL) in pregnancy is considerably higher than in previousstudiesoutsidepregnancy(8,9,11).”
Self-citationTechnology in the management of type 1 diabetes mellitus — current status and future prospects
Tauschmann, M., & Hovorka, R. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0044-y · Cited by 183
Self-citationBally, L., Thabit, H., Kojzar, H., Mader, J. K., Qerimi-Hyseni, J., Hartnell, S., Tauschmann, M., Allen, J. M., Wilinska, M. E., Pieber, T. R., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30001-3 · Cited by 150
Self-citationPinsker, J. E., Lee, J. B., Dassau, E., Seborg, D. E., Bradley, P. K., Gondhalekar, R., Bevier, W. C., Huyett, L., Zisser, H. C., & Doyle, F. J. (2016) · Diabetes Care · doi:10.2337/dc15-2344 · Cited by 151
Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions
Templer, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.919942 · Cited by 182
Haidar, A., Tsoukas, M. A., Bernier-Twardy, S., Yale, J.-F., Rutkowski, J., Bossy, A., Pytka, E., El Fathi, A., Strauss, N., & Legault, L. (2020) · Diabetes Care · doi:10.2337/dc19-1922 · Cited by 138
“are still reported with the artificial pancreas (5–8 h/day above 10mmol/L) (4,5), particularly postprandially.”
BackgroundHybrid closed‐loop therapy: Where are we in 2021?
Leelarathna, L., Choudhary, P., Wilmot, E. G., Lumb, A., Street, T., Kar, P., & Ng, S. M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14273 · Cited by 141
Self-citationThe Artificial Pancreas: How Closed-Loop Control Is Revolutionizing Diabetes
Haidar, A. (2016) · IEEE Control Systems · doi:10.1109/mcs.2016.2584318 · Cited by 164
“Adaptive model predictive control that employs an interacting multiple model estimator [60] has also been developed and tested in a three-month clinical trial [72], but details of the adaptation methodology have not been published.”
InfluentialClosed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial
Thabit, H., Hartnell, S., Allen, J. M., Lake, A., Wilinska, M. E., Ruan, Y., Evans, M. L., Coll, A. P., & Hovorka, R. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30280-7 · Cited by 137
Self-citationKovatchev, B., Cheng, P., Anderson, S. M., Pinsker, J. E., Boscari, F., Buckingham, B. A., Doyle, F. J., Hood, K. K., Brown, S. A., Breton, M. D., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0333 · Cited by 141
Self-citationRecent progress in design and preparation of glucose-responsive insulin delivery systems
Shen, D., Yu, H., Wang, L., Khan, A., Haq, F., Chen, X., Huang, Q. Y., & Teng, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.014 · Cited by 146
Sherr, J. L., Heinemann, L., Fleming, G. A., Bergenstal, R. M., Bruttomesso, D., Hanaire, H., Holl, R. W., Petrie, J. R., Peters, A. L., & Evans, M. (2022) · Diabetes Care · doi:10.2337/dci22-0018 · Cited by 136
Self-citationBarnard, K. D., Wysocki, T., Ully, V., Mader, J. K., Pieber, T. R., Thabit, H., Tauschmann, M., Leelarathna, L., Hartnell, S., Acerini, C. L., et al. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817702656 · Cited by 126
Self-citationSherr, J. L., Heinemann, L., Fleming, G. A., Bergenstal, R. M., Bruttomesso, D., Hanaire, H., Holl, R. W., Petrie, J. R., Peters, A. L., & Evans, M. (2023) · Diabetologia · doi:10.1007/s00125-022-05744-z · Cited by 123
Self-citationTauschmann, M., Allen, J. M., Wilinska, M. E., Thabit, H., Stewart, Z., Cheng, P., Kollman, C., Acerini, C. L., Dunger, D. B., & Hovorka, R. (2016) · Diabetes Care · doi:10.2337/dc15-2078 · Cited by 127
Self-citationAbraham, M. B., de Bock, M., Smith, G. J., Dart, J., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., McAuley, S. A., Keech, A. C., et al. (2021) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2021.3965 · Cited by 121
Boughton, C. K., Hartnell, S., Thabit, H., Mubita, W. M., Draxlbauer, K., Poettler, T., Wilinska, M. E., Hood, K. K., Mader, J. K., Narendran, P., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00005-8 · Cited by 127
Self-citationPsychosocial impacts of hybrid closed‐loop systems in the management of diabetes: a review
Farrington, C. (2018) · Diabetic Medicine · doi:10.1111/dme.13567 · Cited by 121
Latres, E., Finan, D. A., Greenstein, J. L., Kowalski, A., & Kieffer, T. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.007 · Cited by 117
Taleb, N., Emami, A., Suppère, C., Messier, V., Legault, L., Ladouceur, M., Chiasson, J., Haidar, A., & RABASA-LHORET, R. P. R. (2016) · Diabetologia · doi:10.1007/s00125-016-4107-0 · Cited by 133
“Previous studies have compared conventional insulin pump therapy to either a single-hormone or dual-hormone artificial pancreas during exercise [15, 26].”
A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems
Peacock, S., Frizelle, I., & Hussain, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01394-5 · Cited by 122
Bell, K. J., Toschi, E., Steil, G. M., & Wolpert, H. A. (2016) · Diabetes Care · doi:10.2337/dc15-2855 · Cited by 121
“used in artificial pancreas systems (13).”
Multinational Home Use of Closed-Loop Control Is Safe and Effective
Anderson, S. M., Raghinaru, D., Pinsker, J. E., Boscari, F., Renard, E., Buckingham, B. A., Nimri, R., Doyle, F. J., Brown, S. A., Keith-Hynes, P., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2468 · Cited by 120
Self-citationBlauw, H., van Bon, A. C., Koops, R., DeVries, J. H., & O. B. O. T. P. C. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12663 · Cited by 115
“Hybrid closed-loop insulin delivery systems have successfully been used in long-term home studies overnight [1], during the evening and night [2], and during the day and night [3].”
BackgroundMcAuley, S. A., Trawley, S., Vogrin, S., Ward, G. M., Fourlanos, S., Grills, C. A., Lee, M. H., Alipoor, A. M., O’Neal, D. N., O’Regan, N. A., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1667 · Cited by 117
Jacobs, P. G., El Youssef, J., Reddy, R., Resalat, N., Branigan, D., Condon, J., Preiser, N., Ramsey, K., Jones, M., Edwards, C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12707 · Cited by 116
“Hovorka et al.(2) recently showed that, for people with T1D, glucose control could be improved when using a singlehormonal AP system for 12 weeks under free-living conditions com-”
BackgroundResultBiester, T., Berget, C., Boughton, C. K., Cudizio, L., Ekhlaspour, L., Hilliard, M. E., Reddy, L., Sap, S. N. U., Schoelwer, M. J., Sherr, J. L., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543034 · Cited by 124
Gingras, V., Taleb, N., Roy‐Fleming, A., Legault, L., & Rabasa‐Lhoret, R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13052 · Cited by 113
“In this study, the hybrid CLS, as compared with sensoraugmented pump therapy, improved time in target range for glucose levels while reducing mean glycaemia and time spent in hypoglycaemia.(31) However, even with the hybrid CLS in which preprandial glucose values are generally improved, postprandial glucose control re…”
Personalized glucose forecasting for type 2 diabetes using data assimilation
Albers, D. J., Levine, M., Gluckman, B., Ginsberg, H., Hripcsak, G., & Mamykina, L. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005232 · Cited by 106
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Moon, S. J., Jung, I., & Park, C.-Y. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0177 · Cited by 98
“For the insulin-only closed-loop system, the main groups comprise the companies CamDiab (Cambridge, UK), DreaMed (Petah Tikva, Israel), Medtronic (Minneapolis, MN, USA), and TypeZero Technology (Charlottesville, VA, USA) [24,25,28,45].”
BackgroundDomingo‐Lopez, D. A., Lattanzi, G., Schreiber, L. H. J., Wallace, E. J., Wylie, R., O’Sullivan, J., Dolan, E. B., & Duffy, G. P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114280 · Cited by 125
Iturralde, E., Tanenbaum, M. L., Hanes, S. J., Suttiratana, S. C., Ambrosino, J. M., Ly, T. T., Maahs, D. M., Naranjo, D., Walders-Abramson, N., Weinzimer, S. A., et al. (2017) · The Diabetes Educator · doi:10.1177/0145721717697244 · Cited by 103
Is an artificial pancreas (closed‐loop system) for Type 1 diabetes effective?
Boughton, C. K., & Hovorka, R. (2019) · Diabetic Medicine · doi:10.1111/dme.13816 · Cited by 100
Self-citationClosed-Loop Control Without Meal Announcement in Type 1 Diabetes
Cameron, F. M., Ly, T. T., Buckingham, B. A., Maahs, D. M., Forlenza, G. P., Levy, C. J., Lam, D., Clinton, P., Messer, L. H., Westfall, E., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0078 · Cited by 105
“Although our system has this implicit risk, it demonstrated comparable time spent below 70 mg/dL.(17,18) The time spent <70 mg/dL was partly mitigated by subjects being immediately treated for any meter BG <70 mg/dL, and if the subject had symptoms of hypoglycemia even if their glucose was >70 mg/dL.”
BackgroundScholten, K., & Meng, E. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.02.022 · Cited by 102
“of clinical studies have explored ad hoc closed-loop systems comprising a mix of research and commercial devices (Bergenstal et al., 2016; Kovatchev et al., 2014; Kropff et al., 2015; Leelarathna et al., 2014; Renard et al., 2016; Tauschmann et al., 2016; Thabit et al., 2014; Thabit et al., 2015).”
BackgroundRenard, E., Farret, A., Kropff, J., Bruttomesso, D., Messori, M., Place, J., Visentin, R., Calore, R., Toffanin, C., Di Palma, F., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0008 · Cited by 104
Tauschmann, M., Allen, J. M., Nagl, K., Fritsch, M., Yong, J., Metcalfe, E., Schaeffer, D., Fichelle, M., Schierloh, U., Thiele, A. G., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1881 · Cited by 100
“Results of the current study are consistent with observations in older children (6), adolescents (6,7), adults (6,9), and pregnant women (20) about safety and efficacy of closed-loop therapy using Cambridge model predictive control.”
ResultSelf-citationRealizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes
Lal, R. A., Ekhlaspour, L., Hood, K., & Buckingham, B. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00174 · Cited by 95
Zeng, B., Gao, L., Yang, Q., Jia, H., & Sun, F. (2023) · Diabetes Care · doi:10.2337/dc23-0504 · Cited by 100
Dovc, K., Boughton, C., Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Acerini, C. L., Arnolds, S., de Beaufort, C., Bergenstal, R. M., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2625 · Cited by 97
“5 mmol/mol) in two studies (5,8), and in two studies there was no lower threshold (6,7).”
BackgroundSelf-citationContinuous Glucose Monitoring, Future Products, and Update on Worldwide Artificial Pancreas Projects
Kropff, J., & DeVries, J. H. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0345 · Cited by 96
“Most of the improvement in glycemia took place during the night period.(40) This seems due to the challenging daytime circumstances with glucose perturbations due to physical activity and carbohydrate intake during meals and snacks.”
InfluentialThe Artificial Pancreas in 2016: A Digital Treatment Ecosystem for Diabetes
Kovatchev, B., Tamborlane, W. V., Cefalu, W. T., & Cobelli, C. (2016) · Diabetes Care · doi:10.2337/dc16-0824 · Cited by 95
Del Favero, S., Boscari, F., Messori, M., Rabbone, I., Bonfanti, R., Sabbion, A., Iafusco, D., Schiaffini, R., Visentin, R., Calore, R., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2815 · Cited by 94
Sharifi, A., De Bock, M. I., Jayawardene, D., Loh, M. M., Horsburgh, J. C., Berthold, C. L., Paramalingam, N., Bach, L. A., Colman, P. G., Davis, E. A., et al. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0288 · Cited by 91
Karageorgiou, V., Papaioannou, T. G., Bellos, I., Alexandraki, K., Tentolouris, N., Stefanadis, C., Chrousos, G. P., & Tousoulis, D. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.002 · Cited by 89
“The only available information comes from one study [25], which reported a non-significant decrease (−0.”
BackgroundClosed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy
Fuchs, J., & Hovorka, R. (2020) · Expert Review of Medical Devices · doi:10.1080/17434440.2020.1784724 · Cited by 82
“Thabit et al conducted a twelve week open-label randomised crossover study comparing the closed-loop system to sensor augmented pump therapy in 33 adults (55), while Tauschmann et al reported a similarly designed study enrolling 86 participants aged 6 years and older with suboptimal glycaemic control (56).”
BackgroundSelf-citationType 1 Diabetes in Children and Adolescents
Wherrett, D. K., Ho, J., Huot, C., Legault, L., Nakhla, M. M., & Rosolowsky, E. T. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.036 · Cited by 114
“Results from several studies are promising for outcomes combining a lowering of the number of hypoglycemic events while optimizing per cent time in target range for glucose, fasting blood glucose and mean sensor glucose (45).”
BackgroundRemote patient monitoring using artificial intelligence
Jeddi, Z., & Bohr, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818438-7.00009-5 · Cited by 132
Pease, A., Lo, C., Earnest, A., Kiriakova, V., Liew, D., & Zoungas, S. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0417 · Cited by 83
Bergenstal, R. M., Johnson, M., Passi, R., Bhargava, A., Young, N., Kruger, D. F., Bashan, E., Bisgaier, S. G., Isaman, D. J. M., & Hodish, I. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30368-x · Cited by 88
“children and adults using a hybrid closed-loop insulin delivery system, reduced their HbA1c from an average of ~8⋅5% (~69mmol/mol) to ~7⋅5% (~58mmol/mol) in 12 weeks(12).”
Dassau, E., Pinsker, J. E., Kudva, Y. C., Brown, S. A., Gondhalekar, R., Dalla Man, C., Patek, S., Schiavon, M., Dadlani, V., Dasanayake, I., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1188 · Cited by 85
The Hybrid Closed-Loop System: Evolution and Practical Applications
Weaver, K. W., & Hirsch, I. B. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0091 · Cited by 84
Dovc, K., Macedoni, M., Bratina, N., Lepej, D., Nimri, R., Atlas, E., Muller, I., Kordonouri, O., Biester, T., Danne, T., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4395-z · Cited by 85
Sleep in type 1 diabetes: implications for glycemic control and diabetes management
Perez, K. M., Hamburger, E. R., Lyttle, M., Williams, R., Bergner, E., Kahanda, S., Cobry, E., & Jaser, S. S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0974-8 · Cited by 86
Haidar, A., Messier, V., Legault, L., Ladouceur, M., & Rabasa‐Lhoret, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12880 · Cited by 81
Tauschmann, M., Allen, J. M., Wilinska, M. E., Thabit, H., Acerini, C. L., Dunger, D. B., & Hovorka, R. (2016) · Diabetes Care · doi:10.2337/dc16-1094 · Cited by 81
Self-citationGlucose Control in the ICU: A Continuing Story
Preiser, J., Chase, J. G., Hovorka, R., Joseph, J. I., Krinsley, J. S., Block, C. E. M. D., Desaive, T., Foubert, L. A., Kalfon, P., Pielmeier, U., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816648713 · Cited by 88
Self-citationJayawardene, D., McAuley, S. A., Horsburgh, J. C., Gerche, A. L., Jenkins, A. J., Ward, G. M., MacIsaac, R. J., Roberts, T. J., Grosman, B., Kurtz, N., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0461 · Cited by 82
“Recent studies have demonstrated the glycemic benefits of closed-loop versus open-loop insulin delivery for people with type 1 diabetes.(8,25,26) However, there remain limitations to current closed-loop systems and strategies proposed to minimize hypoglycemia with exercise.”
A machine-learning approach to predict postprandial hypoglycemia
Seo, W., Lee, Y., Lee, S., Jin, S., & Park, S. (2019) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-019-0943-4 · Cited by 95
“…is a standard of care for tight glycemic control in people with diabetes, to prevent or delay long-term complications of diabetes mellitus [1–3] However, insulin therapy may cause life threatening hypoglycemia and thus achieving and maintaining near normoglycemia is largely limited by this…”
BackgroundZhong, A., Choudhary, P., McMahon, C., Agrawal, P., Welsh, J. B., Cordero, T. L., & Kaufman, F. R. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0216 · Cited by 77
“In other outpatient studies, HCL systems outperformed sensoraugmented pumps in terms of glucose control, time in hypoglycemia, and glycated hemoglobin levels.(16,17) The MiniMed 640G system is the first commercially available system to offer predictive suspension and automatic resumption, based on SG, of basal insulin…”
BackgroundForlenza, G. P., Buckingham, B. A., Brown, S. A., Bode, B. W., Levy, C. J., Criego, A. B., Wadwa, R. P., Cobry, E. C., Slover, R. J., Messer, L. H., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0546 · Cited by 78
Godoi, A., Reis Marques, I., Padrão, E. M. H., Mahesh, A., Hespanhol, L. C., Riceto Loyola Júnior, J. E., de Souza, I. A. F., Moreira, V. C. S., Silva, C. H., Miyawaki, I. A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01144-4 · Cited by 67
“Most studies in our analysis did not assess fully automated systems [8, 29, 31–38, 40– 46], which still require manual Finally, this was the first meta-analysis to assess how long-term use of AID impacts patient-reported outcomes with a considerable number of studies.”
BackgroundMethodJiao, X., Shen, Y., & Chen, Y. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002633 · Cited by 76
“However, the CLS group weighed more than the control group after treatment (SMD=0.19 kg, 95% CI 0.03 to 0.36 kg, p=0.02; online supplemental appendix 12).”
InfluentialDual‐hormone artificial pancreas: benefits and limitations compared with single‐hormone systems
Peters, T. M., & Haidar, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13581 · Cited by 71
Prediction of hypoglycemia during aerobic exercise in adults with type 1 diabetes
Reddy, R., Resalat, N., Wilson, L. M., Castle, J. R., El Youssef, J., & Jacobs, P. G. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818823792 · Cited by 75
Joseph, J. I. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820911919 · Cited by 81
Ruan, Y., Thabit, H., Leelarathna, L., Hartnell, S., Willinska, M. E., Dellweg, S., Benesch, C., Mader, J. K., Holzer, M., Kojzar, H., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2623 · Cited by 70
Self-citationRuan, Y., Wilinska, M. E., Thabit, H., & Hovorka, R. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2590498 · Cited by 71
Self-citationThe molecular mechanisms by which vitamin D improve glucose homeostasis: A mechanistic review
Yaribeygi, H., Maleki, M., Sathyapalan, T., Iranpanah, H., Orafai, H. M., Jamialahmadi, T., & Sahebkar, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117305 · Cited by 80
Metadata
- Authors
- Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., Mader, J. K., Holzer, M., Kojzar, H., Exall, J., Yong, J., Pichierri, J., Barnard, K. D., Kollman, C., Cheng, P., Hindmarsh, P. C., Campbell, F. M., Arnolds, S., Pieber, T. R., Evans, M. L., Dunger, D. B., & Hovorka, R.
- Affiliations
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Profil Institute for Metabolic Research (DE)
- Medical University of Graz (AT)
- Leeds Teaching Hospitals NHS Trust (GB)
- University College Hospital (GB)
- Bournemouth University (GB)
- Jaeb Center for Health Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2129-2140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4697362
- OpenAlex
- W2332531077
- Cited by
- 450
- References
- 29
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 23 · 2023: 29 · 2022: 31 · 2021: 43 · 2020: 34 · 2019: 49 · 2018: 71 · 2017: 71 · 2016: 68 · 2015: 10
- FWCI
- 63.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Wellcome Trust (100574, 100574/Z/12/Z)
- National Institute for Health and Care Research (NF-SI-0508-10274, NF-SI-0513-10012, CAMBRC-2012-1)
- Swansea University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, artificial beta cell, sensor-augmented pump therapy, glycemic variability, HbA1c, children and adolescents, adults, continuous glucose monitoring, insulin pump therapy, free-living conditions, hypoglycemia risk reduction, glycemic control
- MeSH terms
- Adolescent, Adult, Algorithms, Child, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Infusion Pumps, Implantable, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.